The World Intellectual Property Organization (WIPO) has published clinical-stage biopharma Tryp Therapeutics Inc. (OTCQB:TRYPF)’s international patent application for the intravenous (IV) administration of psilocybin and psilocin.
The “Improved Methods For The Use of Psychedelics” patent application expands and strengthens the IP of TRP-8803 with an IV formulation of proprietary psilocybin and psilocin, to be administered together with psychotherapy, expected to enhance the psychedelics’ positive effects while reducing the limitations of other administration routes including oral, nasal and sublingual.
